Bastion Technologies has been tapped to provide safety and mission services for NASA's Marshall Space Flight Center in Alabama. Photo via nasa.gov.

NASA has granted Houston-based Bastion Technologies Inc. the Safety and Mission Assurance II (SMAS II) award with a maximum potential value of $400 million.

The award stipulates that the engineering and technical services company provide safety and mission services for the agency’s Marshall Space Flight Center in Huntsville, Alabama, according to a release from NASA.

In the deal, Bastion’s services include system safety, reliability, maintainability, software assurance, quality engineering, independent assessment, institutional safety and pressure systems. Bastion’s work will support research and development projects, hardware fabrication and testing, spaceflight and science missions, and other activities at NASA Marshall, Michoud Assembly Facility in New Orleans, Stennis Space Center in Bay St. Louis, Mississippi, NASA’s Kennedy Space Center in Florida and various other sites.

The first base period for the SMASS II award has already begun, with the option for a base ordering period of four years to extend services through March 2034.

Bastion has been a key player in NASA’s Artemis program, and was also awarded a contract to support occupational safety, health and mission assurance at NASA’s Ames Research Center in Silicon Valley in 2024. Also in 2024, Bastion was awarded the NASA Glenn Research Center (GRC) Environmental, Safety, Health, and Mission Assurance (ESHMA) contract.

Since 1998, Bastion has held over 350 contracts at almost every NASA center and most major aerospace industry partners.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.